Enhancement of delayed hypersensitivity reaction with varieties of anti-cancer drugs. A common biological phenomenon.
Delayed hypersensitivity reaction in mice was commonly enhanced with various anti-cancer agents administered as single or intermittent high doses but not consecutive divided doses. The effect of anti-cancer agents on the delayed hypersensitivity reaction was thought to be due to elimination of suppressor T cell activity.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002225:Carbazilquinone / Q000627:therapeutic use; D002453:Cell Cycle / Q000187:drug effects; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D013852:Thiotepa / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D002225:Carbazilquinone; D003520:Cyclophosphamide; D013852:Thiotepa